List of Scitara DLX Customers
Marlborough, 01752, MA,
United States
Since 2010, our global team of researchers has been studying Scitara DLX customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Scitara DLX for Laboratory Management from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Scitara DLX for Laboratory Management include: Pfizer, a United States based Life Sciences organisation with 81000 employees and revenues of $63.63 billion, Boehringer Ingelheim, a Germany based Life Sciences organisation with 54500 employees and revenues of $28.94 billion, Gilead Sciences, a United States based Life Sciences organisation with 17600 employees and revenues of $28.75 billion, Medline, a United States based Life Sciences organisation with 38000 employees and revenues of $21.20 billion, Teva Pharmaceuticals, a Israel based Life Sciences organisation with 35001 employees and revenues of $15.85 billion and many others.
Contact us if you need a completed and verified list of companies using Scitara DLX, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The Scitara DLX customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
argenx | Life Sciences | 650 | $381M | Netherlands | Scitara | Scitara DLX | Laboratory Management | 2022 | n/a |
In 2022, argenx implemented Scitara DLX as its Laboratory Management platform, deploying the application to support research and laboratory operations. The deployment tied the company, Scitara DLX and Laboratory Management to core R&D workflows, establishing a formal platform for laboratory data orchestration and operational control across its scientific teams.
Scitara DLX was configured to provide sample lifecycle management, instrument connectivity, data orchestration and workflow automation, reflecting capabilities typical of Laboratory Management solutions. Configuration work focused on instrument interfacing, protocol and run management, and structured data capture to support laboratory execution and downstream analysis.
Governance changes accompanied the rollout to standardize laboratory workflows and data governance, aligning cross-functional processes between scientists and lab operations. argenx presented this implementation and its implementation journey alongside Teva Pharmaceuticals and Boehringer Ingelheim to share the impact Scitara DLX has had on their digital transformation.
|
|
|
Astellas Pharma US | Life Sciences | 3000 | $700M | United States | Scitara | Scitara DLX | Laboratory Management | 2019 | n/a |
In 2019, Astellas Pharma US implemented Scitara DLX to support Laboratory Management across its research and technical operations labs and production environments. The deployment was aligned with site level automation ownership in South San Francisco and with cross functional stakeholders in Quality Assurance, Quality Control, Process Development, IT and Facilities, positioning Scitara DLX to centralize instrument connectivity and data capture for GxP workflows.
Configuration work focused on device adapters and protocol bridges for PLCs, SCADA, DCS, OPC DA UA and MODBUS, with services for instrument abstraction, event driven data collection, metadata normalization and secure RDBMS persistence. Functional modules included system administration, device management, real time data capture and historian interfaces, API endpoints for analytics consumption, and dashboarding capabilities embedded within Scitara DLX.
Integrations were implemented to federate data with Aveva PI suite components and enterprise historians, and to feed downstream analytics platforms such as Spotfire and Power BI, alongside ELN and laboratory data platforms including Benchling and Tetrascience. The architecture incorporated cloud technologies such as Azure or AWS for storage and compute, RDBMS backends for normalized results, and OPC UA for secure device telemetry, while ingesting data from laboratory instruments including Cytiva Unicorn and Sartorius BioBrain.
Governance and operationalization emphasized compliance with GAMP and 21 CFR Part 11, and included authoring Functional Specifications, Design Specifications, Configuration Specifications and Automation SOPs. Change Controls, Deviations and CAPAs for automation related changes were managed by automation and quality teams, Level 3 and above technical support was defined for real time processing and controls issues, and automation test protocols and computer system validation practices were embedded into rollout and ongoing operations.
|
|
|
Boehringer Ingelheim | Life Sciences | 54500 | $28.9B | Germany | Scitara | Scitara DLX | Laboratory Management | 2022 | n/a |
In 2022, Boehringer Ingelheim deployed Scitara DLX as a Laboratory Management platform. The implementation positioned Scitara DLX as a centralized data orchestration and instrument connectivity layer to support laboratory operations within research and development.
Scitara DLX was implemented to provide core Laboratory Management capabilities including instrument connectivity, data acquisition and normalization, event-driven workflow orchestration, and audit-ready data logging. Configuration work emphasized protocol adapters and API-ready endpoints typical for laboratory automation, and metadata mapping to preserve data provenance and lineage in laboratory workflows.
Operational focus targeted internal laboratory and R&D functions, where Scitara DLX was used to standardize data capture, automate instrument orchestration, and enforce consistent governance around experiment data handling. The Boehringer Ingelheim Scitara DLX Laboratory Management deployment aligned technical architecture, workflow orchestration, and governance to create a repeatable pattern for lab-level data management.
|
|
|
Eisai | Life Sciences | 10000 | $4.8B | Japan | Scitara | Scitara DLX | Laboratory Management | 2021 | n/a |
In 2021, Eisai implemented Scitara DLX to provide instrument data ingestion and transformation as part of its Laboratory Management stack, centralizing instrument-to-LIMS data flows for regulated QC testing. Scitara DLX was positioned as an instrument data orchestration layer feeding the cloud-hosted LabVantage LIMS v8.7 deployed in a GxP laboratory environment, enabling automated transfer of analytical outputs into LIMS records used for raw material and batch release testing.
Scitara DLX was configured to normalize and transform raw instrument outputs into LIMS-ready formats, supporting downstream ELN and LES workflows and Master Data structures authored for QC testing. The implementation emphasized data integrity and compliance, with Scitara DLX handling ingestion, transformation, and handoff to the Laboratory Management system while preserving auditability required for regulated testing.
The implementation integrated Scitara DLX and LabVantage with multiple enterprise systems, explicitly including SAP S4 HANA, MES, and Veeva QMS, and auxiliary tools such as Bartender for sample labeling and an SPC system validated to detect process deviations. Operational artifacts and validation governance were tightly linked to these integrations, with OQ and PQ protocols authored and uploaded to Veeva, execution findings recorded in JIRA, and printing configuration validated for label compliance.
Governance and operational ownership included dedicated LIMS Business Analyst and Master Data Developer roles, computer system validation activities for LabVantage and integrated components, and ITIL-aligned support and ticketing processes. The approach combined configuration, validation, and master data design to support Laboratory Management business functions in QC, and validated SPC integration that ensured early detection of deviations and alignment with regulatory compliance objectives.
|
|
|
EMD Electronics | Life Sciences | 2000 | $450M | United States | Scitara | Scitara DLX | Laboratory Management | 2024 | n/a |
In 2024, EMD Electronics implemented Scitara DLX as a centralized Laboratory Management platform to unify experimental and instrument data across its semiconductor materials research, enabling machine friendly and human readable datasets. The deployment was positioned as a cloud native, instrument aware integration layer that captures raw files and contextualizes them for downstream analysis and visualization.
The Scitara DLX implementation included functional capabilities for automated data capture from metrology instruments such as ellipsometers and infrared spectrophotometers, bidirectional data routing, and a structured ontology layer for data modeling. Configuration work focused on simultaneous routing so that instrument outputs are sent to Signals Notebook while also populating a relational database, with tooling to select and pull structured datasets into experiment records and dashboards.
Integrations were executed between Scitara integration technology and Revvity Signals Notebook, a relational database, and a downstream data analysis platform, preserving both instrument generated and manually entered experimental data. Operational coverage centered on the semiconductor R&D organization and laboratory IT, with connectivity tied into the corporate network and cloud to enable secure, auditable flows from on premise and cloud resident instruments.
Governance and workflow changes emphasized data structuring through an ontology layer, audit controls, and scientist centric data selection so that users decide which structured datasets populate experiments. As a result explicitly stated in project materials, scientists shifted focus from data management to analysis, creating visualizations and preparing data for AI and machine learning workflows, while the platform roadmap included extracting results from older instruments and adding AI driven agents for predictive insights.
|
|
|
|
Life Sciences | 17600 | $28.8B | United States | Scitara | Scitara DLX | Laboratory Management | 2023 | n/a |
|
|
|
|
Life Sciences | 20 | $3M | United States | Scitara | Scitara DLX | Laboratory Management | 2023 | n/a |
|
|
|
|
Life Sciences | 15000 | $6.0B | United States | Scitara | Scitara DLX | Laboratory Management | 2019 | n/a |
|
|
|
|
Professional Services | 150 | $17M | United States | Scitara | Scitara DLX | Laboratory Management | 2019 | n/a |
|
|
|
|
Life Sciences | 38000 | $21.2B | United States | Scitara | Scitara DLX | Laboratory Management | 2018 | n/a |
|
Buyer Intent: Companies Evaluating Scitara DLX
- Market Gain, a United States based Retail organization with 10 Employees
- Regeneron Pharmaceuticals, a United States based Life Sciences company with 15182 Employees
- Hanmi Pharm, a South Korea based Life Sciences organization with 2400 Employees
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated |
|---|---|---|---|---|---|---|
| Market Gain | Retail | 10 | $1M | United States | 2026-03-30 | |
| Regeneron Pharmaceuticals | Life Sciences | 15182 | $142.0B | United States | 2026-01-09 | |
| Hanmi Pharm | Life Sciences | 2400 | $741M | South Korea | 2025-10-27 | |
| Retail | 100 | $25M | Ireland | 2025-09-23 | ||
| Professional Services | 1000 | $250M | United States | 2025-09-08 |